Tag Archives: Biogen Idec

Xconomy Profile Reveals More About Prothena, Stock Is Still Too Risky

By |
0 Comment

Last month, Elan(ELN) spun off Prothena(PRTA). As we wrote at the time,  Elan gave Prothena $125 million in cash and a research team with no pipeline. Elan itself now consists mostly of Tysabri, a blockbuster drug on which it is partnered with Biogen Idec(BIIB). We have to admit, we knew very little about Prothena, so we were grateful… Read More »

Elan To Spin Off Drug Discovery Business, Neotope Biosciences, By Yearend

By |
0 Comment

What do you do when your drug discovery costs swamp your profits from a successful marketed drug.  If you’re Elan Corporation(ELN), you spin off your drug discovery business with a bundle of cash, keeping your marketed drugs and late stage pipeline. Elan, an Irish biotech firm, is driven largely by Tysabri,a multiple sclerosis drug marketed with Biogen Idec(BIIB).… Read More »